Gibril Fathia, Chen Yuan-Jia, Schrump David S, Vortmeyer Alexander, Zhuang Zhengping, Lubensky Irina A, Reynolds James C, Louie Adeline, Entsuah Laurence K, Huang Kane, Asgharian Behnam, Jensen Robert T
Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health (NIH), Bethesda, Maryland 20892, USA.
J Clin Endocrinol Metab. 2003 Mar;88(3):1066-81. doi: 10.1210/jc.2002-021314.
Little is known of the natural history of thymic carcinoids in multiple endocrine neoplasia type 1 (MEN1). This is important because in 1993 they were identified as a frequent cause of death, yet only small retrospective studies and case reports exist. We report results of a prospective study of 85 patients with MEN1 evaluated for pancreatic endocrine tumors and followed over a mean of 8 yr with serial chest computed tomography, magnetic resonance imaging (MRI), chest x-ray, and, since 1994, octreoscans [somatostatin receptor scintigraphy (SRS)]. Seven patients (8%) developed thymic carcinoids. Patients with and without carcinoids did not differ in clinical, laboratory, or MEN1 tumor features, except for male gender and the presence of a gastric carcinoid. All thymic tumors were hormonally inactive. Four thymic carcinoids lacked 11q loss of heterozygosity, although it was found in three pancreatic endocrine tumors. Computed tomography and/or MRI were more sensitive than SRS or chest x-ray in detecting tumors initially or with recurrence. All patients underwent resection of the thymic carcinoid, and in all patients followed more than 1 yr, the tumor recurred. Bone metastases developed in two patients and were detected early only on MRI, not SRS. This study provides information on early thymic carcinoids and allows modifications of existing guidelines to be recommended for their diagnosis, surveillance, and treatment.
关于1型多发性内分泌腺瘤病(MEN1)中胸腺类癌的自然病史,人们所知甚少。这一点很重要,因为在1993年它们被确定为常见的死亡原因,但仅有小型回顾性研究和病例报告。我们报告了一项对85例MEN1患者进行的前瞻性研究结果,这些患者因胰腺内分泌肿瘤接受评估,并通过系列胸部计算机断层扫描、磁共振成像(MRI)、胸部X线检查,以及自1994年以来的奥曲肽扫描[生长抑素受体闪烁显像(SRS)]进行了平均8年的随访。7例患者(8%)发生了胸腺类癌。有类癌和无类癌的患者在临床、实验室或MEN1肿瘤特征方面无差异,但男性性别和胃类癌的存在除外。所有胸腺肿瘤均无激素活性。4例胸腺类癌缺乏11q杂合性缺失,尽管在3例胰腺内分泌肿瘤中发现了这种缺失。计算机断层扫描和/或MRI在最初检测肿瘤或肿瘤复发时比SRS或胸部X线更敏感。所有患者均接受了胸腺类癌切除术,且在所有随访超过1年的患者中,肿瘤均复发。2例患者发生骨转移,仅通过MRI早期检测到,而非SRS。本研究提供了关于早期胸腺类癌的信息,并允许对现有指南进行修改,以推荐其诊断、监测和治疗方法。